Saturday, June 22, 2024
HomeWellnessDrugs and MedicationsIs off-label prescribing of a prescription drug clinically effective?

Is off-label prescribing of a prescription drug clinically effective?

Concerns are being raised about the clinical efficacy of off-label prescribing. McGill University researchers investigated whether off-label prescribing of a prescription drug is supported by rigorous research.

Pharmaceutical companies developing a new prescription drug are motivated to receive approval from the Food and Drug Administration (FDA) to begin marketing their drug. The FDA approves a drug when its safety and efficacy have been explored and confirmed through clinical trials for at least one indication. Thereafter, secondary uses of the drug are explored in order to expand the use of the prescription drug.

Drug companies are not incentivized to design and perform further expensive clinical trials once their drug is approved. In addition, doctors can prescribe off-label uses of a prescription drug based off of inexpensive exploratory trials. This raises a concern that off-label prescribing may be clinically ineffective.

Researchers at McGill University’s Biomedical Ethics Unit in Montreal, Canada investigated the off-label prescribing of pregabalin. Pregabalin is approved for its use in nerve pain and as an adjunctive treatment for partial onset seizures in adults. Off-label prescribing of pregabalin include generalized anxiety disorder, lower back pain, essential tremor, migraine, post-surgery pain, itchiness, restless legs syndrome, and vasomotor menopausal symptoms. Over 230 clinical trials exploring the efficacy of pregabalin were analyzed and the results were published in JAMA Internal Medicine.

Among the 33 new indications present in the selected studies, over half were only studied in exploratory studies. Most of the selected trials were exploratory and 61% showed positive results. Confirmatory studies are required to test the indication in a larger study to prove its safety and efficacy. This analysis shows that the majority of the research completed on the other indications for use of pregabalin were attempting to explore its use rather than prove that its use is safe and effective.

Exploratory studies that are not followed by confirmatory studies can result in health care providers using incomplete research to prescribe a drug with an off-label use. In this analysis, 63% of the exploratory studies were not followed up by confirmatory studies within the first five years of its publication.

Physicians, patients, and the health care system are left with incomplete information but a possibility for an effective off-label use of pregabalin. One example of this is the off-label use by confirmatory for lower back pain. Pregabalin never went through the appropriate confirmatory studies; therefore, it was never approved to treat lower back pain. Yet, studies show that pregabalin is often used to treat lower back pain. 

Exposing patients to ineffective treatments or for drugs with unproven indications is an unethical practice. Unfortunately, funding for large confirmatory trials is limited once a prescription drug is approved for use. The off-label prescribing of pregabalin is one example of potentially inappropriate uses of a prescription drug based on exploratory studies. The McGill University researchers reinforce the message to ethics committees, drug regulators, funding bodies and health care payers to use their authority to support confirmatory testing of off-label indications of prescription drugs.

Written by Jessica Caporuscio, PharmD

References:

  1. Federico CA, Wang T,Doussau A, Mogil JS, Fergusson D, Kimmelman J.Assessmentof Pregabalin Postapproval Trials and the Suggestion of Efficacy for NewIndications: A Systematic Review. JAMA Intern Med. 2018.
  2. Pregabalin. Lexi-Drugs. Lexicomp. Wolters KluwerHealth, Inc. Riverwoods, IL. Available at: http://online.lexi.com. AccessedNovember 29, 2018.
Jessica Caporuscio PharmD
Jessica Caporuscio PharmD
Jessica received her Doctorate of Pharmacy from the University of Montreal in July 2014 and she has been working as a community pharmacist in the Greater Toronto Area since March 2015. She has a passion to communicate medical and drug information to her patients and other healthcare professionals. Jessica is also a marathoner and an Ironman triathlete. In her spare time, she is in her kitchen creating healthy recipes for her family.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Vitamin D as an Anti Colorectal Cancer Agent in 2024 – a Review of the Evidence

Vitamin D has a protective effect against colorectal cancer, but it is patient and population dependent.According to the WHO, colorectal cancer (CRC) is the...

Joke Of The Day – June 23

If you can read a prescription that you got from a doctor, be careful! Maybe it was not a real doctor…

ADVERTISE WITH US

error: Content is read-only and copy-protected.